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Background: The relationship between myocardial perfusion imaging (MPI) abnormalities, 
diabetes mellitus, and glucose control in South African populations is unknown. It was hypoth-
esized that in subjects undergoing MPI for suspected coronary artery disease (CAD), those with 
diabetes would have more extensive perfusion defects and that diabetes control would influence 
MPI abnormalities. The aim of this study was to examine the relationship between the sever-
ity of CAD diagnosed with MPI in subjects with and without diabetes and to determine the 
relationship between diabetes control and extent of CAD.
Methods: This study was a retrospective chart review of 340 subjects in whom MPI scans 
were performed over a 12-month period.
Results: Subjects with diabetes had a higher prevalence of abnormal MPI, with more extensive 
ischemia, compared with subjects without diabetes (85.6% versus 68%; odds ratio 2.81, P,0.01). 
Glycated hemoglobin $7.0% was associated with a higher risk of abnormal MPI, with more 
extensive ischemia, compared with subjects having diabetes and glycated hemoglobin ,7.0% 
(odds ratio 2.46, P=0.03) and those without diabetes (odds ratio 4.55, P=0.0001).
Conclusion: Subjects with diabetes have more extensive myocardial ischemia when compared 
with subjects without diabetes. Furthermore, poorer diabetes control is associated with more 
abnormalities on MPI scanning.
Keywords: myocardial perfusion imaging, diabetes mellitus, coronary artery disease, glycated 
hemoglobin
Introduction
The prevalence, incidence, and mortality of all forms of cardiovascular disease are 
  2–8-fold higher in persons with diabetes.¹ In addition, diabetes is an established 
“coronary risk-equivalent”, ie, patients with diabetes belong to the same risk category 
as patients with known coronary artery disease (CAD).² Patients with diabetes and 
no history of myocardial infarction have been reported to have as high a risk of both 
myocardial infarction (20% versus 19%) and coronary mortality (15% versus 16%) 
as patients without diabetes who have a history of myocardial infarction.³
Identification of the presence and severity of CAD in subjects with type 2 diabetes 
is hampered by the poor sensitivity of electrocardiographic (ECG) tests, and further 
testing is often required for a definitive diagnosis.4 Coronary angiography is still the 
gold standard for identification of CAD, despite the existence of different modalities 
of noninvasive imaging studies, as the temporal and spatial resolution of conventional Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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coronary angiography is higher than any noninvasive study.5 
Furthermore, despite results of noninvasive studies showing 
ischemia, a significant proportion of these patients do not 
have ischemic disease on conventional coronary angiography 
or are not eligible for revascularization.6 Coronary angiog-
raphy is a costly procedure, with limited availability, and 
carries a risk of complications due to its invasive nature, so 
it is not feasible or available for many patients.4 Myocardial 
perfusion imaging (MPI) is a screening test used for the 
diagnosis and estimation of the extent and severity of CAD, 
and is reported to have similar diagnostic accuracy for CAD 
in subjects with and without diabetes mellitus.7
Several reports have compared MPI with other forms 
of stress imaging in the diagnosis of CAD. A meta-analysis 
compared the performance of an exercise tolerance test 
(ETT), single photon-emission computed tomographic 
(SPECT)-MPI with both exercise and pharmacologic stress, 
and stress echocardiography in patients with a 25%–75% 
pretest risk for coronary artery disease. Coronary angiog-
raphy was performed for each positive test.8 The study   
reported that ETT had a sensitivity of 68% and specificity of 
77%, thallium SPECT-MPI a sensitivity of 88% and speci-
ficity of 77%, and stress echocardiography a sensitivity of 
76% and specificity of 88% in the diagnosis of CAD, when 
compared with coronary angiography. Other reports have 
suggested that the severity of MPI abnormalities in patients 
with diabetes is a predictor of future myocardial infarction 
and cardiac death, and the use of stress MPI in conjunction 
with clinical information can provide risk stratification in 
these patients.9,10
Control of hyperglycemia and modification of other 
CAD risk factors is essential for the prevention of CAD and 
its complications in subjects with type 2 diabetes. Several 
studies have examined the relationship between long-term 
glucose control, measured by glycated hemoglobin (HbA1c) 
in patients with diabetes, and the extent and severity of 
CAD.¹¹,¹² DeLuca et al noted that the prevalence of silent 
myocardial ischemia detected by stress or pharmacologi-
cal MPI in patients who had no previous history of CAD 
was greater in those with diabetes than in those without 
diabetes. In addition, the prevalence of silent myocardial 
ischemia was greater in patients with poorly controlled 
diabetes (HbA1c .7.6%) as compared with those with 
optimal glycemic control (HbA1c ,7.6%).¹¹ Another study 
found that the risk for abnormal MPI and the prevalence 
of myocardial ischemia (detected by MPI) was greater in 
subjects with diabetes than in subjects without diabetes, 
and more abnormalities were found in those with poor 
  glycemic control.¹² Similarly, Ravipati et al noted that 
higher HbA1c levels were associated with more severe 
angiographically determined CAD.¹³
The current study aimed to examine the relationship 
between the extent and severity of CAD, diagnosed with 
MPI, in relation to the presence of diabetes and other CAD 
risk factors. The hypothesis was that patients with diabetes 
have more abnormal and severe perfusion defects compared 
with those without diabetes, with increased risk in those with 
poor long-term glycemic control.
Materials and methods
Study population and patient selection
This was a retrospective chart review of 340 patients referred 
for MPI studies to the Department of Cardiology at Inkosi 
Albert Luthuli Central Hospital in Durban, KwaZulu-Natal, 
between January 1, 2012 and December 31, 2012.
Data collection
Electronic medical records were used to access patient demo-
graphic and relevant medical history, including the diagnosis 
of diabetes, hypertension, prior CAD, use of lipid-lowering 
medication and aspirin, smoking, and other risk factors. In 
this study, subjects with diabetes were defined as individu-
als taking anti-hyperglycemic agents (oral agents, insulin, 
or combination) while subjects with dyslipidemia were 
defined as individuals taking lipid-lowering medications or 
with abnormal lipid levels (total cholesterol $5.18 mmol/L, 
  triglycerides $1.7 mmol/L, low-density lipoprotein 
  cholesterol $2.59 mmol/L, and high-density lipoprotein cho-
lesterol ,1.0 mmol/L in males or ,1.3 mmol/L in females). 
Glycemic control was considered optimal if HbA1c 
was ,7.0% (53 mmol/mol) and was considered to be sub-
optimal if HbA1c was $7.0% (53 mmol/mol).   Hypertension 
was diagnosed if patients were taking anti-hypertensive 
medication, and smoking was defined as current smokers, 
according to the medical records.
Results of a resting ECG, exercise treadmill tests, and 
echocardiography were obtained from the medical records. 
An abnormal ECG was defined as one showing either an 
ischemic or infarct pattern. An abnormal ETT was defined 
as one showing an ischemic pattern during stress. Abnormal 
echocardiography was defined as the presence of a valvular 
abnormality, abnormal wall motion, or signs of left ven-
tricular dysfunction. Finally, abnormal wall motion was 
defined as either hypokinesia or akinesia. In addition, results 
of biochemical tests, including plasma glucose, HbA1c, 
serum lipids, and creatinine were recorded. The presence or Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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absence of microalbuminuria was determined by a spot urine 
albumin/creatinine ratio exceeding 3.5 mg/mmol in females 
and 2.5 mg/mmol in males.
MPi protocol
All patients completed either a symptom-limited exercise 
test using a standard Bruce protocol or received a weight-
based dipyridamole infusion over 4 minutes followed by 
4   minutes of low-level treadmill exercise, if tolerated.¹4 
A 2-day imaging protocol (stress-rest) was performed using 
15 mCi of technetium 99m-sestamibi injected at the peak of 
stress for stress imaging on the first day, and the same dose of 
technetium 99m-sestamibi for rest imaging at least 24 hours 
after stress imaging. Imaging started 30–60 minutes after the 
stress injection and 60–90 minutes after the rest injection.14
SPECT was performed while the patient was in a 
supine position and gated acquisition (step and shoot with 
32–64 steps separated by 3°–6°) was undertaken on the 
stress images. In the vast majority (95%), the images were 
interpreted without attenuation correction. Attenuation cor-
rection was done only in those patients with a very high 
body mass index (BMI). Images and figures were analyzed 
with MPI (Siemens Corridor 4DM V501) and reviewed by a 
nuclear physician and cardiologist together. The rest and stress 
transaxial slices were uploaded to be automatically processed 
and analyzed by the described software. The results were then 
displayed as functional maps, where the degree of ischemia 
was presented along the representative segments. The same 
data processed through the same program will produce identi-
cal results and there is no subjective interpretation. Agreement 
was reached between the cardiologist and nuclear physician, 
with ,5% interobserver variability. A study was interpreted 
as abnormal if there was evidence of ischemia, infarction, or 
a combination. Ischemia was defined as stress-induced reduc-
tion in myocardial tracer uptake which reversed by more than 
10% with rest, and infarction was defined as a fixed reduction 
in myocardial tracer uptake. Both reversible and fixed reduc-
tion in myocardial tracer uptake could occur in different areas 
of the heart in a single patient.
The summed difference score was used for stratifica-
tion of ischemia into mild (2–4.99), moderate (5–7), and 
severe (.7) grades. The score is derived from the difference 
between two semi-quantitative scores, ie, the summed stress 
score, which detects the extent and severity of perfusion 
defect during stress, and the summed rest score, which detects 
the extent and severity of perfusion defect during rest. These 
scores have been shown to have substantial diagnostic value 
in the assessment of CAD.15
Statistical analysis
Statistical Package for the Social Sciences version 21.0 software 
(IBM Corporation, Armonk, NY, USA) was used to analyze 
the data. The chi-squared test was used for categorical variables 
and the Student’s t-test was used for continuous variables. 
The Mann–Whitney test was used to compare subjects with 
and without diabetes and the well-controlled versus poorly 
controlled patients with diabetes; the test variable was the 
MPI result. In addition, subjects with a normal MPI scan were 
compared with those with an abnormal scan. Multiple linear 
regression analysis was used to assess the effect of diabetes 
duration, HbA1c, lipid levels, blood pressure, smoking, and 
other risk factors on the severity of CAD. Bonferroni correction 
was used to calculate the differences in the degree of ischemia. 
A P-value ,0.05 was regarded as statistically significant.
Results
clinical and laboratory results
Table 1 shows the clinical and laboratory characteristics of 
the study group. The total study group included 340 subjects, 
of whom 146 (43%) did not have diabetes and 194 (57%) 
had diabetes.
When compared with subjects without diabetes, those 
with diabetes were older, more had a diagnosis of hyperten-
sion, dyslipidemia, and a family history of diabetes, and 
more were using anti-hypertensive medications. In addition, 
subjects with diabetes had a higher BMI, systolic blood 
pressure (BP), serum creatinine, plasma glucose, and HbA1c, 
and a greater frequency of proteinuria or microalbuminuria. 
There was no significant difference between the groups for 
sex, ethnic group, smoking history, history of CAD, history 
of peripheral vascular disease, history of cardiovascular 
disease, diastolic BP, lipid levels (total cholesterol, triglyc-
erides, high-density lipoprotein cholesterol, and low-density 
lipoprotein cholesterol), or use of aspirin or anti-ischemic and 
lipid-lowering agents. In addition, there was no difference in 
ECG, ETT, or echocardiographic findings.
MPi study
normal versus abnormal
Seventy-four (22%) subjects had normal MPI scans and 
266 (78%) had abnormal MPI scans (Table 2). When compared 
with those who had normal MPI scans, the group with abnormal 
scans included more males and smokers, and were more likely 
to have diabetes, a family history of CAD, and peripheral vas-
cular disease. In addition, subjects with abnormal MPI had a 
higher plasma glucose, HbA1c, total cholesterol, and low-density 
lipoprotein cholesterol, were more likely to be on anti-ischemic Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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medications, and more likely to have an abnormal ECG and 
abnormal echocardiography. Subjects with abnormal MPI had a 
lower BMI and lower systolic BP. An abnormal ETT, duration 
of diabetes, and nature of treatment for hyperglycemia were 
not associated with an abnormal MPI scan.
Diabetes versus no diabetes
When subjects with diabetes were compared with those with-
out diabetes (Table 3), an abnormal MPI was more frequent 
in those with diabetes. In addition, both MPI ischemia and 
infarction were more frequently demonstrated in those with 
diabetes.
Diabetes control and MPi result
Of the subjects with diabetes, 88 patients (45%) had an 
HbA1c ,7.0% and 106 patients (55%) had an HbA1c $7.0%. 
When subjects with poor glycemic control were compared 
with those with optimal glycemic control (Table 4), an abnor-
mal MPI was more frequent in those with HbA1c $7.0%. 
The subjects with diabetes and poor glycemic control more 
often had an abnormal MPI when compared with subjects 
without diabetes (Table 5). In addition, MPI ischemia and 
infarction were more frequently demonstrated in those who 
Table 1   clinical  and  laboratory  characteristics  of  the  study 
subjects (n=340)
No diabetes 
(n=146)
Diabetes 
(n=194)
P-value
age (years) 55±11.2 58±9.5 0.01
Sex 
  Male (n=211) 
  Female (n=129)
 
91 (62.3) 
55 (37.7)
 
120 (61.9) 
74 (38.1)
nS
ethnic group 
  african (n=46) 
  indian (n=246) 
  White (n=42) 
  Others (n=6)
 
24 (16.4) 
98 (67.1) 
21 (14.4) 
3 (2.1)
 
22 (11.3) 
148 (76.2) 
21 (11) 
3 (1.5)
nS
hypertension 84 (57.5) 163 (84) ,0.001
Dyslipidemia 91 (62.3) 150 (77.3) ,0.01
Smoking 91 (62.3) 111 (57.2) nS
history of caD 124 (84.9) 151 (77.8) nS
Family history of diabetes 1 (0.7) 10 (5.2) 0.02
Treatment for  
hypertension
82 (56.2) 165 (85) ,0.001
anti-ischemic treatment 123 (84.2) 154 (79.4) nS
lipid-lowering agents 134 (91.8) 187 (95.4) nS
aspirin treatment 132 (90.4) 172 (88.7) nS
BMi (kg/m2) 27.9±5.8 29.7±6.2 ,0.01
SBP (mmhg) 131±22 138±23 ,0.01
DBP (mmhg) 75.79±12.39 76.07±12.25 nS
Plasma glucose (mmol/l) 5.5±0.6 8.7±2.8 ,0.001
hba1c (%, mmol/mol) 5.8 (40)±0.4 7.8 (62)±1.8 ,0.001
Serum creatinine  
(μmol/l)
79.6±18.3 128.1±139.1 ,0.001
Proteinuria or 
microalbuminuria
10 (6.8) 48 (24.7) ,0.001
abnormal ecg 119 (81.5) 165 (85.1) nS
abnormal eTT 28 (19.2) 46 (23.7) nS
abnormal  
echocardiogram
102 (69.9) 139 (71.6) nS
abnormal echo  
wall motion
90 (62) 128 (66) nS
ejection fraction (%) 55±17 57±18 nS
Note: results are expressed as the mean ± standard deviation or n (%).
Abbreviations:  BMi,  body  mass  index;  caD,  coronary  artery  disease;  DBP, 
diastolic  blood  pressure;  ecg,  electrocardiograph;  eTT,  exercise  treadmill  test; 
echo, echocardiographic; hba1c, glycated hemoglobin; SBP, systolic blood pressure; 
NS, not statistically significant.
Table 2   comparison  of  subjects  with  normal  and  abnormal 
MPi results
Normal MPI 
(n=74 )
Abnormal MPI 
(n=266 )
P-value
age (years) 57±10 57±11 nS
Sex 
  Male (n=211) 
  Female (n=129)
 
29 (39.2) 
45 (60.8)
 
182 (68.4) 
84 (31.6)
 
,0.001
Diabetes 31 (41.9) 163 (61.3) ,0.01
Diabetes  
duration (years)
10±7 11±7 nS
hypertension 57 (77) 190 (71.4) nS
Dyslipidemia 48 (64.9) 193 (72.6) nS
Smoking 34 (45.9) 168 (63.2) ,0.01
history of caD 50 (67.6) 225 (84.6) ,0.01
Family history  
of diabetes
3 (4.1) 8 (3) nS
Treatment for  
hypertension
56 (76) 191 (71.8) nS
anti-ischemic  
treatment
51 (69) 226 (85) ,0.01
aspirin treatment 60 (81.1) 244 (91.7) ,0.01
lipid-lowering agents 66 (89.2) 255 (95.8) nS
BMi (kg/m2) 31±7 28±6 ,0.01
SBP (mmhg) 144±25 132±21 ,0.001
DBP (mmhg) 78±14 75±12 nS
Plasma glucose  
(mmol/l)
6.5±2.0 7.5±2.8 ,0.001
hba1c (%, mmol/mol) 6.2 (44)±1.0 7.1 (55)±1.8 ,0.001
Total cholesterol  
(mmol/l)
4.29±0.87 4.64±1.2 ,0.01
Proteinuria  
or microalbuminuria
11 (14.9) 47 (17.7) nS
abnormal ecg 54 (73) 230 (86.5) 0.02
abnormal eTT 13 (17.6) 61 (23) nS
abnormal  
echocardiogram
42 (56.8) 199 (74.8) ,0.01
abnormal echo  
wall motion
37 (50) 181 (68.6) ,0.01
ejection fraction (%) 76±7 58±18 ,0.001
Note: results are expressed as mean ± standard deviation or n (%). 
Abbreviations:  BMi,  body  mass  index;  caD,  coronary  artery  disease;  DBP, 
diastolic blood pressure; ecg, electrocardiograph; eTT, exercise treadmill test; 
echo, echocardiographic; hba1c, glycated hemoglobin; SBP, systolic blood pressure; 
MPI, myocardial perfusion imaging; NS, not statistically significant.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Table 3 results of MPi in subjects with (n=194) and without diabetes mellitus (n=146)
MPI result No diabetes 
(n=146)
Diabetes 
(n=194)
OR 95% CI P-value
abnormal MPi 99 (68) 166 (85.6) 2.81 1.65–4.78 ,0.01
ischemia* 62 (42.4) 125 (64.4) 5.46 3.27–9.11 ,0.01
  Mild 20 (32.3) 33 (26.4) 0.75 0.38–1.46 0.4
  Moderate 12 (19.4) 12 (9.6) 0.44 0.18–1.05 0.06
  Severe 30 (48.4) 80 (64) 1.89 1.02–3.51 0.04
infarction 90 (61.6) 150 (77.3) 2.12 1.32–3.40 0.001
Notes: Results are expressed as n (%). *Ischemia defined by summed difference score: mild 2–4.99, moderate 5–7, and severe .7. 
Abbreviations: MPI, myocardial perfusion imaging; CI, confidence interval; OR, odds ratio.
Table 4 Myocardial perfusion imaging results in subjects with diabetes mellitus based on glycemic control
MPI result Diabetes with HbA1c  
,7.0% (n=88)
Diabetes with HbA1c  
$7.0% (n=106)
OR 95% CI P-value
abnormal MPi 70 (79.5) 96 (90.6) 2.46 1.07–5.67 0.03
ischemia* 49 (55.7) 76 (71.7) 2.01 1.11–3.66 0.02
  Mild 18 (36.7) 15 (19.7) 0.42 0.18–0.95 0.03
  Moderate 5 (10.2) 7 (9.2) 0.89 0.26–2.98 0.85
  Severe 26 (53.1) 54 (71.1) 2.17 1.02–4.59 0.04
infarction 59 (67) 91 (85.8) 2.98 1.47–6.03 0.002
Notes: Results are expressed as n (%). *Ischemia defined by summed difference score: mild 2–4.99, moderate 5–7, and severe .7. 
Abbreviations: MPI, myocardial perfusion imaging; CI, confidence interval; OR, odds ratio; HbA1c, glycated hemoglobin.
had poor glycemic control compared with those who had 
optimal glycemic control and when compared with those 
without diabetes.
grade of ischemia and diabetes status
Despite ischemia being more common overall in subjects 
with diabetes than in those without diabetes, there was no sig-
nificant difference between the groups for each level of isch-
emia as defined by the summed difference score (Table 3). 
However, in the subjects with diabetes, mild ischemia was 
more often found in subjects with HbA1c ,7.0% (Table 4). 
More severe ischemia was found in the subjects with diabetes 
compared with subjects without diabetes (Table 3), and in 
subjects with diabetes and HbA1c $7.0% (Tables 4 and 5). 
After Bonferroni correction, a significant difference remained 
between moderate and severe MPI ischemia in subjects with 
diabetes compared with those without diabetes (P=0.007).
Multiple linear regression analysis was used to assess 
the effect of diabetes duration, HbA1c, lipid levels, blood 
pressure, smoking, and other risk factors for severity of 
CAD. None of the risk factors were significant, as depicted 
in Table 6.
Discussion
In this study, abnormal MPI scans were more often found in 
men and those with diabetes, dyslipidemia, and   abnormal 
ECG and echocardiography. In subjects with diabetes, 
there was a higher prevalence of CAD risk factors and MPI 
  evidence of ischemia and infarction. The frequency and 
severity of MPI abnormalities was higher in diabetic subjects 
with poor glycemic control.
All patients in the current study were referred to a tertiary 
cardiology service for assessment of possible CAD, and there-
fore represent a group of subjects in whom risk factors for or 
symptoms of CAD had been identified. CAD is a major cause 
of morbidity and mortality in subjects with diabetes,16 and the 
current study has shown both MPI-defined myocardial ischemia 
and infarction to be more common in the group with diabetes. 
Amongst the risk factors examined for CAD, the study showed 
older age, higher BMI, more frequent hypertension, higher 
systolic BP, and lipid abnormalities in the group with diabetes 
when compared with the group without diabetes.
The UK Prospective Diabetes Study showed that better 
glycemic control was associated with a reduction in both 
CAD prevalence and mortality after a mean of 10 years of 
follow-up.¹7 Although this is a cross-sectional and retrospec-
tive study, poorer glycemic control amongst the subjects with 
diabetes was associated with more extensive ischemia and 
infarction on MPI scanning. These findings are in accord 
with those reported by DeLuca et al and Nicole et al.¹¹,¹² In 
a retrospective chart review, DeLuca et al demonstrated that 
the prevalence of silent myocardial ischemia detected by MPI 
in diabetic patients who had no known CAD was higher in 
those with HbA1c $7.6% than in those with HbA1c ,7.6% Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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Table 6 Multiple linear regression analysis results
Risk factor P-value
age (years) 0.74
Sex 
ethnic group
0.35 
0.06
Diabetes duration (years) 0.55
hypertension 0.57
Dyslipidemia 0.52
Smoking 0.72
history of caD 0.40
Family history of diabetes 0.95
Family history of caD 0.34
BMi (kg/m2) 0.27
SBP (mmhg) 0.42
DBP (mmhg) 0.21
Plasma glucose (mmol/l) 0.19
hba1c (%, mmol/mol) 0.29
Total cholesterol (mmol/l) 0.26
Triglycerides 1.00
hDl 0.47
lDl 0.09
Proteinuria or microalbuminuria 0.99
Abbreviations:  BMi,  body  mass  index;  caD,  coronary  artery  disease;  DBP 
diastolic blood pressure; hba1c, glycated hemoglobin; hDl, high-density lipoprotein; 
lDl, low-density lipoprotein; SBP, systolic blood pressure.
Table 5 MPi results in subjects without diabetes (n=146) and those with diabetes and hba1c $7.0% (n=106)
MPI result No diabetes 
(n=146)
Diabetes with HbA1c  
$7.0% (n=106)
OR 95% CI P-value
abnormal MPi 99 (68) 96 (90.6) 4.55 2.17–9.53 0.0001
ischemia* 62 (42.4) 76 (71.7) 3.43 2.01–5.86 ,0.0001
  Mild 20 (32.3) 15 (19.7) 0.51 0.23–1.12 0.09
  Moderate 12 (19.4) 7 (9.2) 0.42 0.15–1.14 0.09
  Severe 30 (48.4) 54 (71.1) 2.61 1.29–5.28 0.007
infarction 90 (61.6) 91 (85.8) 3.77 1.99–7.15 ,0.0001
Notes: Results are expressed as n (%). *Ischemia defined by summed difference score: mild 2–4.99, moderate 5–7, and severe .7. 
Abbreviations: hba1c, glycated hemoglobin; MPI, myocardial perfusion imaging; CI, confidence interval; OR, odds ratio.
(50% versus 28%, P,0.005). Nicole et al demonstrated 
that the risk and prevalence of abnormal MPI (ischemia, 
infarction, or mixed defect) in patients with symptoms of 
CAD was greater in diabetic patients than in those without 
diabetes (41% versus 28%, P,0.001). In the same study, MPI 
abnormality was more severe in those with diabetes and poor 
glycemic control (HbA1c $7.0%) than in nondiabetic patients 
(41% versus 28%, P=0.02), and the prevalence of abnormal 
MPI scans increased as HbA1c increased (46% of diabetes 
with HbA1c $8.0% versus 28% of nondiabetics, P=0.02).
In the current study, when the subjects with diabetes were 
grouped according to HbA1c, mild ischemia (as defined by 
the summed difference score) was more common in those 
with HbA1c ,7.0%, lending further support to the notion that 
glycemic control plays an important role in both the extent 
and severity of CAD in subjects with diabetes.
In this study, a family history of diabetes was found more 
often in the group with diabetes, but there was no association 
between MPI abnormalities and family history. Other studies 
have shown a strong association between family history and 
atherosclerosis, measured by carotid-intima media thickness, 
even in subjects with normal glucose tolerance.18 It is pos-
sible that the retrospective nature of the current study may 
have weakened the association with family history. A recent 
review has further highlighted the importance of family his-
tory as a risk factor for atherosclerosis and emphasized the 
role of prediabetes as an additional important risk factor.19 No 
data on prediabetes were collected in the present study.
Despite the association between more prevalent and 
severe MPI abnormalities and presence of diabetes, duration 
of known diabetes was not associated with MPI-defined CAD 
in the current study. This may be accounted for by the nature 
of the study (retrospective, cross-sectional) or by underdiag-
nosis of diabetes prior to the onset of ischemic symptoms 
that would prompt diagnostic testing.
The retrospective nature of this study is a limitation in 
that reliance was placed on the accuracy of available medical 
records. Furthermore, the study is limited by referral bias, 
since the majority of patients were referred for MPI on the 
basis of presence of symptoms, and the majority had multiple 
CAD risk factors.
Screening for the presence of asymptomatic CAD in 
subjects with diabetes is hampered by the limited sensitivity 
and specificity of noninvasive diagnostic modalities. Previous 
studies have shown that the ETT has a sensitivity of 68% and 
specificity of 77% for diagnosis of CAD.²0 In subjects with 
an abnormal MPI scan, an abnormal resting ECG was more 
often present in those with MPI-defined CAD, but there was 
no association with an abnormal ETT. Several factors could 
account for this, including autonomic neuropathy, which may 
impair exercise tolerance as well as affect the heart rate, BP, 
and cardiac output responses to exercise.²¹ Poor physical 
fitness and other comorbidities, such as peripheral vascular Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2014:7 submit your manuscript | www.dovepress.com
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disease, would also interfere with the ability of the patient 
to exercise to a level high enough to produce meaningful 
results on ETT. In addition, baseline ECG abnormalities, 
such as left ventricular hypertrophy and resting ST-segment 
changes, are common in patients with diabetes and this may 
interfere with interpretation of the ETT.
Other noninvasive modalities that provide useful 
information on the presence and extent of atherosclerosis 
in subjects at risk for CAD include use of ultrasound to 
determine flow-mediated vasodilatation, anteroposterior 
abdominal aorta diameter, and intima-media thickness 
of the common carotid artery, as recently reviewed by 
  Ciccone et al.²² These modalities were not evaluated in 
the current study.
It is not feasible to perform coronary angiography in 
large numbers of patients with suspected CAD, so accurate 
noninvasive screening tools are required to assist in risk 
stratification. This is particularly important in subjects with 
diabetes, in whom ECG-based screening methods have 
limited sensitivity.²³ While MPI scanning is more costly and 
less widely available than ECG-based diagnostic tools, it has 
the advantage of the ability to distinguish areas of reversible 
ischemia from areas of fixed ischemia, as well as to more 
accurately map the vascular territories affected. In addition, 
functional detail is obtained by measurement of ejection 
fraction, making this a useful noninvasive tool to evaluate 
CAD in subjects with diabetes.
Conclusion
The current study has shown that subjects with diabetes 
carry a greater burden of CAD than those without diabetes. 
Furthermore, poorer glycemic control is associated with 
more severe CAD. MPI scanning is a useful tool in the 
assessment of these patients, providing more information 
than   ECG-based diagnostic investigations.
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